Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
ARGATROBAN IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, and XIII, and platelet aggregation.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Continuous IV infusion: 2 mcg/kg/min, adjusted to maintain aPTT 1.5-3 times baseline. Maximum initial infusion rate is 10 mcg/kg/min.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
None Documented
None Documented
Terminal elimination half-life is 39–51 minutes in healthy subjects; prolonged to 181–269 minutes in patients with hepatic impairment. Clinical context: Short half-life allows rapid reversal of anticoagulation upon discontinuation.
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Primarily hepatic (biliary) excretion: approximately 65% eliminated via bile into feces; renal excretion accounts for about 22% as unchanged drug and metabolites.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Category A/B
Category C
Electrolyte
Electrolyte